We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Low Levels of Prohormone Predicts Coronary Heart Disease

By LabMedica International staff writers
Posted on 24 Nov 2014
Print article
Image:  The Agilent 6890 GC with 5973 Mass Spectrometer and Tekmar Velocity XPT Purge & Trap (Photo courtesy of Gen Tech).
Image: The Agilent 6890 GC with 5973 Mass Spectrometer and Tekmar Velocity XPT Purge & Trap (Photo courtesy of Gen Tech).
The adrenal sex hormone dehydroepiandrosterone (DHEA), which is present in serum mainly as the sulfate DHEA-S, is the most abundant steroid hormone in human blood and its levels decline dramatically with age.

DHEA is a prohormone that is produced by the adrenal glands and can be converted to active sex hormones and men with low levels of DHEA in the blood run, and maybe a predictor of, an increased risk of developing coronary heart disease (CHD) events.

Scientists at the Sahlgrenska Academy (University of Gothenburg, Sweden) and their colleagues used gas and liquid chromatography-mass spectrometry to analyze baseline levels of DHEA and DHEA-S in a prospective population-based study in Sweden of 2,416 men, ages 69 to 81 years. They monitored the men for five years and complete cardiovascular clinical outcomes were available from national Swedish registers. The analytes and the internal standard were detected using the HP5973 quadrupole mass spectrometer (Agilent Technologies; Santa Clara, CA, USA) equipped with a chemical ionization source.

There were 302 participants who experienced a CHD event, and 225 had a cerebrovascular disease (CBD) event during the five-year follow-up. Both DHEA and DHEA-S levels were inversely associated with the age-adjusted risk of a CHD event; the hazard ratios and 95% confidence intervals per standard deviation (SD) increase were 0.82 (0.73 to 0.93) and 0.86 (0.77 to 0.97), respectively. In contrast, DHEA-S showed no statistically significant association with the risk of CBD events. The association between DHEA and CHD risk remained significant after adjustment for traditional cardiovascular risk factors, serum total testosterone and estradiol, C-reactive protein, and renal function, and remained unchanged after exclusion of the first 2.6 years of follow-up to reduce reverse causality.

The authors concluded that low serum levels of DHEA and its sulfate predict an increased risk of CHD, but not CBD, events in elderly men. Åsa Tivesten, MD, PhD, the lead author of the study said, “Endogenous production of DHEA appears to be a protective factor against coronary heart disease. High DHEA levels may also be a biomarker of generally good health in elderly men.” The study was published on October 21, 2014, in the Journal of the American College of Cardiology.

Related Links:

Sahlgrenska Academy 
Agilent Technologies 


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Urine Analyzer
URIT-180
New
Toxoplasma Rapid Test
Toxo IgG/IgM Rapid Test Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.